Sglt2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease however they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of hellip.

Treatment with dapagliflozin reduced the incidence of new onset type 2 diabetes in participants with chronic kidney disease and hf without a reduction in hba1c.